Table 2. Activities of Select Quinazolinones against a Gram-Positive Panel of Bacteria.
| MIC (μg/mL) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| strain | 2a | 15 | 27 | 30 | 50 | 52 | 54 | vancomycin | linezolid |
| S. aureus ATCC 29213b | 2 | 0.03 | 0.03 | 1 | 0.5 | 0.25 | 0.004 | 1 | 2 |
| S. aureus ATCC 27660c | 8 | 0.5 | 0.06 | 2 | 0.5 | 1 | 0.25 | 1 | 2 |
| S. aureus NRS100 (COL)d | 16 | 0.25 | 0.25 | 8 | 4 | 1 | 0.5 | 2 | 2 |
| S. aureus NRS119d | 8 | 0.125 | 0.06 | 2 | 4 | 0.25 | 0.5 | 2 | 32 |
| S. aureus NRS120d | 8 | 0.125 | 0.5 | 8 | 4 | 0.25 | 0.25 | 2 | 32 |
| S. aureus VRS1e | 16 | 0.5 | 0.5 | 8 | 8 | 4 | 0.5 | 512 | 2 |
| S. aureus VRS2f | 2 | 0.06 | 0.03 | 1 | 4 | 0.125 | 0.125 | 64 | 2 |
| S. epidermis ATCC 35547 | 1 | 0.125 | 0.008 | 0.125 | 0.125 | 0.06 | 0.125 | 16 | 1 |
| S. haemolyticus ATCC 29970 | 1 | 0.125 | 0.008 | 0.25 | 1 | 0.25 | 0.125 | 2 | 2 |
| S. oralis ATCC 9811 | >128 | >128 | 128 | 128 | >128 | >128 | >128 | 0.5 | 1 |
| S. pyogenes ATCC 49399 | >128 | >128 | 128 | 128 | >128 | >128 | >128 | 0.5 | 1 |
| B. cereus ATCC 13061 | >128 | >128 | 128 | >128 | >128 | >128 | >128 | 1 | 1 |
| B. licheniformis ATCC 12759 | >128 | >128 | 128 | >128 | >128 | >128 | >128 | 0.5 | 1 |
| E. faecalis ATCC 29212b | >128 | 128 | >128 | >128 | >128 | 128 | >128 | 2 | 2 |
| E. faecalis 99g | >128 | 64 | 128 | >128 | 16 | 64 | 128 | 128 | 1 |
| E. faecium NCTC 7171 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | 0.5 | 2 |
a
Data reproduced from Bouley et al. for comparison.
b
Quality control strain for susceptibility testing.
c
mecA positive, resistant to methicillin, oxacillin, and tetracycline.
d
mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid.
e
Vancomycin-resistant MRSA (vanA) clinical isolate from Michigan.
f
Vancomycin-resistant MRSA (vanA) clinical isolate from Pennsylvania.
g
Vancomycin-resistant clinical isolate.